Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| DiaMedica Therapeutics Inc | DMAC | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.59 | 06:08:35 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.59 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.57 - 4.75 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 2.59 | USD |
DiaMedica Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 98.3M | 37.95M | - | 0 | -13.68M | -0.36 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
DiaMedica Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DMAC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.51 | 2.60 | 2.40 | 2.52 | 7,423 | 0.08 | 3.19% |
| 1 Month | 2.72 | 3.20 | 2.26 | 2.67 | 35,741 | -0.13 | -4.78% |
| 3 Months | 2.86 | 3.34 | 2.26 | 2.84 | 38,146 | -0.27 | -9.44% |
| 6 Months | 2.12 | 3.34 | 2.10 | 2.74 | 43,953 | 0.47 | 22.17% |
| 1 Year | 1.70 | 4.75 | 1.57 | 3.12 | 79,772 | 0.89 | 52.35% |
| 3 Years | 9.23 | 9.84 | 1.12 | 3.41 | 108,926 | -6.64 | -71.94% |
| 5 Years | 3.29 | 10.88 | 1.12 | 4.38 | 101,225 | -0.70 | -21.28% |
DiaMedica Therapeutics Description
| DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1. |
